Fighting AMD: the power of nutrition

Article

With a greater understanding of how ocular nutrition affects sight, ophthalmologists need to encourage healthy diets with nutrients and antioxidants essential for healthy vision.

The National Eye Institute's (NEI) first Age-Related Eye Disease Study (AREDS) in 2008 demonstrated that oral supplementation with antioxidant vitamins C and E, beta-carotene and zinc reduced risk of progression to advanced AMD by 25% in high-risk patients.2,3

The 2013 AREDS2 follow-up study found that long-term use (10 years) of the high-dose antioxidant-plus-zinc formula reduced the risk of developing advanced AMD by 34%.

The NEI chose a brand lutein product (Flora-GLO Lutein, Kemin Health/DSM) for the study because it is the only purified lutein that is the same as the lutein molecule found in nature.

Participants who took the AREDS formulation with lutein and zeaxanthin had an 18% reduced risk of developing advanced AMD over the 5-year study. Participants who had low levels and intake of lutein and zeaxanthin before the study began were 25% less likely to develop advanced AMD compared with participants with similar dietary intake who were not taking lutein and zeaxanthin supplements.4

The power of patient education

For best eye health, older adults and those at risk of vision loss due to AMD should take vitamins containing 10 mg of lutein and 2 mg of zeaxanthin. Yet, few people are getting the lutein and zeaxanthin they need. According to the National Health and Nutrition Examination Survey in the US, a mere 41% of Americans are familiar with lutein, and only 6% have ever heard of zeaxanthin.5

Encouraging diets that contain essential nutrients and antioxidants for healthy vision - and recommending supplements for nutrients like vitamin E, lutein and zeaxanthin where diet alone does not meet daily recommendations - is crucial to the sustained health of eye care patients globally.

References

1. S. Resnikoff et al., Bull. World Health Organ., 2004;82(11):844–851.

2. http://www.nei.nih.gov/news/pressreleases/101201.asp

3. http://www.ncbi.nlm.nih.gov/pubmed/11594942

4. http://www.nei.nih.gov/news/pressreleases/050513.asp

5. NHANES 2003–2008.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.